循環器ジャーナル71巻1号

2023年01月発行

特集 ここが変わった！循環器診療 最新スタンダード Ⅰ．疾患各論

遺伝性不整脈

著者： 大野聖子¹

所属機関： ¹国立循環器病研究センター分子生物学部

ページ範囲：P.69 - P.75

ここが変わった！
●過去のスタンダード
　・遺伝性不整脈は非常に稀な疾患で，日常診療で診断する機会は少ない．
　・無症状の患者に対する予防的治療は不要である．
　・遺伝学的検査は治療法選択や予後予測に有用ではない．
●現在のスタンダード
　・健康診断などで心電図異常を指摘され，診断される症例も多い．
　・無症状患者であってもリスク層別化は可能であり，予防的介入が実施される．
　・一部の遺伝性不整脈によっては，遺伝型によって治療法が異なり，予後予測も可能となっている．

参考文献

1）Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome : from genetics to management. Circ Arrhythm Electrophysiol 2012 ; 5 : 868-77.

2）Fukuyama M, Horie M, Aoki H, et al. School-based routine screenings of electrocardiograms for the diagnosis of long QT syndrome. Europace 2022 ; 24 : 1496-503.

3）日本循環器学会．遺伝性不整脈の診療に関するガイドライン（2017年改訂版）．2018

4）Splawski I, Timothy KW, Sharpe LM, et al. Ca（V）1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004 ; 119 : 19-31.

5）Fukuyama M, Wang Q, Kato K, et al. Long QT syndrome type 8 : novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace 2014 ; 16 : 1828-37.

6）Makita N, Yagihara N, Crotti L, et al. Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet 2014 ; 7 : 466-74.

7）Crotti L, Spazzolini C, Tester DJ, et al. Calmodulin mutations and life-threatening cardiac arrhythmias : insights from the International Calmodulinopathy Registry. Eur Heart J 2019 ; 40 : 2964-75.

8）Koopmann TT, Alders M, Jongbloed RJ, et al. Long QT syndrome caused by a large duplication in the KCNH2（HERG）gene undetectable by current polymerase chain reaction-based exon-scanning methodologies. Heart Rhythm 2006 ; 3 : 52-5.

9）Mazzanti A, Maragna R, Vacanti G, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol 2018 ; 71 : 1663-71.

10）Wilde AA, Moss AJ, Kaufman ES, et al. Clinical Aspects of Type 3 Long-QT Syndrome : An International Multicenter Study. Circulation 2016 ; 134 : 872-82.

11）Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. Circ Arrhythm Electrophysiol 2019 ; 12 : e007280.

12）Dusi V, Pugliese L, De Ferrari GM, et al. Left Cardiac Sympathetic Denervation for Long QT Syndrome : 50 Years' Experience Provides Guidance for Management. JACC Clin Electrophysiol 2022 ; 8 : 281-94.

13）Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013 ; 10 : 1932-63.

14）Shimamoto K, Ohno S, Kato K, et al. Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1. Heart 2022 ; 108（11） : 840-847.

15）Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association（EHRA）/Heart Rhythm Society（HRS）/Asia Pacific Heart Rhythm Society（APHRS）/Latin American Heart Rhythm Society（LAHRS）Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace 2022 ; 24 : 1307-67.

16）Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on beta-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2022 ; 145 : 333-44.

17）Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009 ; 15 : 380-3.

18）van der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J 2019 ; 40 : 2953-61.

19）Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J 2022 ; 43 : 2096-102.

20）Hosseini SM, Kim R, Udupa S, et al. Reappraisal of Reported Genes for Sudden Arrhythmic Death : Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. Circulation 2018 ; 138 : 1195-205.

21）Barc J, Tadros R, Glinge C, et al. Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nat Genet 2022 ; 54 : 232-9.

22）Ishikawa T, Kimoto H, Mishima H, et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J 2021 ; 42 : 2854-63.

23）Thorsen K, Dam VS, Kjaer-Sorensen K, et al. Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome. Nat Commun 2017 ; 8 : 1696.